Lipocine Inc. cash flow to debt ratio of -2.17K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lipocine Inc.'s free cash flow has decreased 644.34% from $-1.31M last year to $-9.76M, signaling decreasing performance

Lipocine Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Lipocine Inc. has insufficient data to evaluate this check.

Lipocine Inc. has a net cash position, so leverage is healthy.

Lipocine Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Lipocine Inc.'s profit margin has decreased (1.01M%) in the last year from 0.07% to -755.13%, signaling decreasing performance

Lipocine Inc.'s short-term assets of $16.88M exceed its short-term liabilities of $2.53M

Lipocine Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lipocine Inc.'s return on equity of -64.75%, is lower than 15.00%, indicating bad performance

Lipocine Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lipocine Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Lipocine Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lipocine Inc. has negative free cash flow, indicating cash burn

Lipocine Inc.'s yearly earnings has decreased 115.37K% since last year from $8.35K to $-9.63M, signaling decreasing performance

Lipocine Inc.'s yearly revenue has decreased 82.35% since last year from $11.20M to $1.98M, signaling decreasing performance

ROIC -57.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lipocine Inc.'s 3-year revenue CAGR of 58.12% is positive, indicating growing revenue over the past 3 years

Lipocine Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Lipocine Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Lipocine Inc. has insufficient data to evaluate this check.

Lipocine Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lipocine Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lipocine Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lipocine Inc. has insufficient data to evaluate this check.

Lipocine Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lipocine Inc. has a price-to-book ratio of 0.79x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Lipocine Inc. has a price-to-sales ratio of 10.99x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue